Comparative Pharmacology
Head-to-head clinical analysis: AMNESTEEM versus TRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTEEM versus TRETINOIN.
AMNESTEEM vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
0.5-1.0 mg/kg/day orally in 2 divided doses
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid